Low-Molecular-Weight Heparins for VTE Prophylaxis and Treatment

Introduction to Dalteparin and Enoxaparin

The American College of Cardiology and other guideline societies recommend the use of low-molecular-weight heparins, such as dalteparin and enoxaparin, for VTE prophylaxis and treatment, with specific considerations for renal insufficiency and cancer-associated VTE 1, 2

Dalteparin is produced through nitrous acid depolymerization of unfractionated heparin, resulting in distinct molecular weight distributions and pharmacokinetic profiles 1
Enoxaparin is manufactured by benzylation followed by alkaline depolymerization, leading to different anti-Xa/anti-IIa ratios and pharmacokinetic properties 1, 3

The National Comprehensive Cancer Network recommends enoxaparin for both prophylaxis and immediate treatment of VTE, as well as for acute coronary syndromes 2, 3, 4, 5, 6
Dalteparin is approved for VTE prophylaxis and extended treatment of symptomatic VTE in cancer patients, with a Category 1 recommendation for cancer-associated VTE treatment 2, 3, 4

For severe renal insufficiency (CrCl <30 mL/min), the National Comprehensive Cancer Network recommends dose reduction of enoxaparin to 30 mg subcutaneously once daily for prophylaxis and 1 mg/kg subcutaneously every 24 hours for treatment 2, 7
Dalteparin may be safer in renal dysfunction, with no specific FDA dose adjustment recommendations, but requires careful consideration of patient factors 2, 4, 7

Standard prophylactic dosing for enoxaparin is 40 mg subcutaneously once daily, while dalteparin is dosed at 5,000 units subcutaneously once daily, with both providing equivalent efficacy for DVT prophylaxis in general surgical and medical patients 1, 9, 10
Treatment dosing for enoxaparin is 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg once daily, while dalteparin is dosed at 200 units/kg subcutaneously once daily initially, then reduced to 150 units/kg daily after 1 month for extended therapy 2, 4, 7

The European Society of Cardiology recommends enoxaparin for acute coronary syndromes, based on superior evidence versus unfractionated heparin 5, 6
Dalteparin has the strongest evidence for extended VTE treatment in cancer patients, with a Category 1 recommendation from the National Comprehensive Cancer Network 4

Neither agent requires routine laboratory monitoring in most patients, but anti-Xa monitoring may be considered in extreme body weights or renal impairment 1, 2, 3, 11
The American College of Cardiology and other guideline societies recommend careful consideration of patient factors, including renal function and body weight, when selecting between dalteparin and enoxaparin 1, 2, 9